- Details
- Oliver Sartor speaks with Louise Emmett about combination therapy approaches with lutetium-PSMA in prostate cancer. The discussion explores various combination strategies, including promising results from the ENZA-p trial combining lutetium-PSMA with enzalutamide, which shows notable response rates in first-line mCRPC. They examine multiple potential combination approaches, including hormonal ther...
|
- Details
- Oliver Sartor hosts Jake Berchuck to discuss a novel epigenomic liquid biopsy platform for determining PSMA expression in prostate cancer. Dr. Berchuck explains how the assay analyzes cell-free DNA to infer tumor PSMA expression, showing strong correlation with PSMA PET scan results. They explore the potential of this technology to provide real-time, non-invasive monitoring of tumor drug target ex...
|
- Details
- Oliver Sartor and Ken Herrmann discuss the current state and future directions of PSMA ligand therapy in prostate cancer treatment. Dr. Herrmann presents recent findings from various clinical trials, including PSMAfore and ENZA-p, which explore the use of lutetium-PSMA therapy in different stages of prostate cancer. They examine the potential of combining lutetium-PSMA with other treatments like e...
|
- Details
- Zachary Klaassen and Phillip Koo discuss the results from the COBRA study, focusing on the innovative 64Cu-SAR-bisPSMA PET imaging presented at ASCO 2024. Dr. Koo explains that this new imaging agent has unique dual binding sites and advanced chelator technology, enhancing its attachment to prostate cancer cells and increasing the detection rate. The COBRA trial reveals that imaging performed the...
|
- Details
- Phillip Koo hosts a discussion on patient selection for radioligand therapy (RLT) in prostate cancer, featuring Amir Iravani and Evan Yu. The conversation delves into complex clinical decisions involving advanced prostate cancer management. Dr. Iravani presents a patient case to illustrate challenges faced in treatment progression, highlighting the patient’s journey through various therapies inclu...
|
- Details
- Dan George discusses the collaborative effort in managing PLUVICTO® therapy for prostate cancer with team members Kristen Davis, a Physician Assistant, and Sarah Wood, a Nurse Practitioner. Kristen describes the meticulous process of vetting patients for PLUVICTO® therapy, which includes reviewing patient information, scans, and coordinating with various departments for approval. Sarah outlines he...
|
- Details
- Phillip Koo engages in a conversation with Ephraim Parent on the pivotal role of PSMA PET imaging in selecting patients for radioligand therapy (RLT). Dr. Parent emphasizes the critical importance of accurately identifying patients through PSMA PET imaging to ensure successful outcomes with Pluvicto therapy. He outlines the standardized practice of evaluating patients with PSMA PET to detect PSMA-...
|
- Details
- Alicia Morgans interviews Matthew Rettig about the evolving treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) within the veterans' healthcare system. Dr. Rettig highlights the VA's infrastructure that supports comprehensive care, including genetic analyses, access to a wide range of medications, and innovative telehealth programs that extend expert care to veterans in...
|
- Details
- Evan Yu and Oliver Sartor discuss the VISION trial's exploration of predictive and prognostic markers in the treatment of prostate cancer with Lutetium-PSMA-617. Sartor clarifies the distinction between predictive and prognostic markers, emphasizing the trial's focus on baseline markers and their association with treatment outcomes. The conversation highlights the importance of PSMA PET scans in p...
|
- Details
- Alicia Morgans engages in a conversation with Oliver Sartor about the evolving landscape of Radioligand Therapy in metastatic castration-resistant prostate cancer (mCRPC). Dr. Sartor discusses the trials in progress for each PSMAfore, SPLASH, and ECLIPSE trials. Dr. Sartor notes the trials are not complete and with little to no data the treatments are not yet ready for widespread clinical applicat...
|
